PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases

Completed · Not applicable

Conditions studied: Cardiac Disease, Dementia, Inflammatory Disease, Fever of Unknown Origin, Vasculitis, Osteomyelitis, FDG Avid Cancers

In brief

This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac diseases, or neurologic diseases. PET-MRI combines two imaging methods that can be used to evaluate disease. PET-MRI is similar to standard-of-care PET-CT, but exposes the patient to less radiation. It is not yet known whether PET-MRI produces better image quality than PET-CT in diagnosing patients with cancer, cardiac disease, or neurologic disease.

Key facts

Study ID

NCT02084147

Run by

Case Comprehensive Cancer Center

People needed

72

Starts

2013-03-07

Expected to finish

2018-10-02

Last updated by the study team

2019-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinically indicated PET/PET-CT (with or without clinically indicated diagnostic MRI)
• Presenting with one of the four conditions specified below
• Fludeoxyglucose F 18 (FDG) avid cancers
• Cardiac disease (cardiac viability assessment)
• Neurologic disorders (dementia)
• Inflammatory disease (for example fever of unknown origin, vasculitis, osteomyelitis)

You may not qualify if…

• Pregnancy and lactation
• Contraindications to undergo MRI
• Cardiac pacemaker and metal devices (as specified in a separate MRI Informed consent)
• Claustrophobia or inability to tolerate MRI examination (lay still for approximately 1 hour and hold breath intermittently)
• Previously known allergies against MRI contrast agents (exclusion criterion only for contrast enhanced MRI)
• Renal insufficiency: glomerular filtration rate (GFR) < 40ml/min/1.73m\^2 and following European Society of Urogenital Radiology (ESUR) guidelines (exclusion criterion only for contrast enhanced MRI)
• Individuals who are not willing or capable of giving informed consent or assent (with legal guardian consent)

Where it is running

• Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.